Moreover, we found that combined treatment with elesclomol-Cu and a p53 activator markedly reduced HCC cell proliferation both in vitro and in vivo, thereby offering a promising treatment strategy for HCC. This evidence concerns the gene TP53 and hepatocellular carcinoma.